medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-17-96-103medsovet-433Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYФармакогенетика ингибиторов протонной помпыPharmacogenetics of proton pump inhibitorsЛеоноваМ. В.LeonovaM. V.noemail@neicon.ruРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияRussian Medical Research University named after N.I. PirogovRussian Federation20153012201501796103Copyright © Леонова М.В., 20152015Леонова М.В.Leonova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/433

Ингибиторы протонной помпы (ИПП) в настоящее время являются наиболее эффективным классом антисекреторных препаратов и широко применяются в лечении неязвенной диспепсии, рефлюкс-эзофагита и ГЭРБ, язвенной болезни и H. pilory-инфекции, а также НПВП-ассоциированных поражений желудка. Несмотря на общий механизм действия и фармакологические эффекты препаратов данного класса, в клинической практике наблюдается межиндивидуальная вариабельность влияния на продукцию кислоты, зависящая от фармакокинетических и фармакогенетических факторов. В результате наблюдается снижение клинической эффективности лечения кислотозависимых заболеваний и эрадикационной терапии против H. pilory.

Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased.

ингибиторы протонной помпыэрадикационная терапияproton pump inhibitorseradication therapyReferencesMaLfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut, 2012. 61: 646-64.MaLfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut, 2012. 61: 646-64.Kuo CH, Kuo FC, Hu HM et al. The optimal first-line therapy of Helicobacter pylori infection in year 2012. Gastroenterol Res Pract, 2012. Article ID 168361, 8 pages. doi:10.1155/2012/168361Kuo CH, Kuo FC, Hu HM et al. The optimal first-line therapy of Helicobacter pylori infection in year 2012. Gastroenterol Res Pract, 2012. Article ID 168361, 8 pages. doi:10.1155/2012/168361Graham DY, Shiotani A. New Concepts of Resistance in the Treatment of Helicobacter pylori Infections. Nat Clin Pract Gastroenterol Hepatol, 2008. 5(6): 321-31.Graham DY, Shiotani A. New Concepts of Resistance in the Treatment of Helicobacter pylori Infections. Nat Clin Pract Gastroenterol Hepatol, 2008. 5(6): 321-31.Kusano M, Kuribayashi S, Kawamura O et al. A Review of the management of gastric acid-related diseases: focus on rabeprazole. Clinical Medicine Insights: Gastroenterology, 2011. 3: 31-43.Kusano M, Kuribayashi S, Kawamura O et al. A Review of the management of gastric acid-related diseases: focus on rabeprazole. Clinical Medicine Insights: Gastroenterology, 2011. 3: 31-43.Kirchheiner J, Glatt S, Fuhr U et al. Relative potency of proton-pump inhibitors - comparison of effects on intragastric pH. Eur J Clin Pharmacol, 2009. 65: 19-31.Kirchheiner J, Glatt S, Fuhr U et al. Relative potency of proton-pump inhibitors - comparison of effects on intragastric pH. Eur J Clin Pharmacol, 2009. 65: 19-31.Kromer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology, 1998. 56: 57-70.Kromer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology, 1998. 56: 57-70.Pantoflickova D, Dorta G, Ravic M et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther, 2003. 17(12): 1507-14.Pantoflickova D, Dorta G, Ravic M et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther, 2003. 17(12): 1507-14.Meyer UA. Metabolic interactions of the protonpump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur. J. Gastroenterol. Hepatol, 1996. 8 (Suppl. 1): S21-S25.Meyer UA. Metabolic interactions of the protonpump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur. J. Gastroenterol. Hepatol, 1996. 8 (Suppl. 1): S21-S25.Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J. Gastroenterol, 2014. 20: 6400-11.Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J. Gastroenterol, 2014. 20: 6400-11.Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs, 2003. 63(24): 2739-54.Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs, 2003. 63(24): 2739-54.Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment. Pharmacol. Ther., 2004. 20(Suppl. 6): 11-9.Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment. Pharmacol. Ther., 2004. 20(Suppl. 6): 11-9.Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol., 2004. 95: 2-8.Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol., 2004. 95: 2-8.Kuo CH, Lu CY, Shih HY. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014. 20(43): 16029-36.Kuo CH, Lu CY, Shih HY. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014. 20(43): 16029-36.Sahara S, Sugimoto M, Uotani T et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolis-ers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther, 2013. 38: 1129-37.Sahara S, Sugimoto M, Uotani T et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolis-ers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther, 2013. 38: 1129-37.Hu YM, Xu JM, Mei О et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacologica Sinica, 2005. 26 (3): 384-8.Hu YM, Xu JM, Mei О et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacologica Sinica, 2005. 26 (3): 384-8.Sim SC, Risinger C, Dahl M-L et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther, 2006. 79: 103-13.Sim SC, Risinger C, Dahl M-L et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther, 2006. 79: 103-13.Li-Wan-Po A, Girard T, Farndon P et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 2010. 69 (3):222-30.Li-Wan-Po A, Girard T, Farndon P et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 2010. 69 (3):222-30.Sugimoto M, Shirai N, Nishino M et al. Rabeprazole 10 mg q.d.s. decreases 24-h intra-gastric acidity significantly more than rabepra-zole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther, 2012. 36: 627-34.Sugimoto M, Shirai N, Nishino M et al. Rabeprazole 10 mg q.d.s. decreases 24-h intra-gastric acidity significantly more than rabepra-zole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther, 2012. 36: 627-34.Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabo-lizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997. 7: 59-64.Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabo-lizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997. 7: 59-64.Мирзаев К.Б., Сычев Д.А., Андреев Д.А. Этнические особенности в Российской Федерации полиморфизма гена cyp2d9, ассоциированного с нарушением ответа на клопидогрел. Молекулярная медицина, 2014. 1: 13-21.Мирзаев К.Б., Сычев Д.А., Андреев Д.А. Этнические особенности в Российской Федерации полиморфизма гена cyp2d9, ассоциированного с нарушением ответа на клопидогрел. Молекулярная медицина, 2014. 1: 13-21.Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther., 2001. 69: 158-68.Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther., 2001. 69: 158-68.Furuta T, Ohashi K, Kamata T et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med, 1998. 129: 1027-30.Furuta T, Ohashi K, Kamata T et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med, 1998. 129: 1027-30.Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res, 2008. 127: 521-30.Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res, 2008. 127: 521-30.Padol S, Yuan Y, Thabane M et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: а meta-analysis. Am. J. Gastroenterol., 2006. 101: 1467-75.Padol S, Yuan Y, Thabane M et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: а meta-analysis. Am. J. Gastroenterol., 2006. 101: 1467-75.Zhao F, Wang J, Yang Y et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter, 2008. 13(6): 532-41.Zhao F, Wang J, Yang Y et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter, 2008. 13(6): 532-41.McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: еsomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther., 2012. 36: 414-425.McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: еsomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther., 2012. 36: 414-425.Tamura T, Kurata M, Inoue ES et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyp-ing. Nagoya J. Med. Sci., 2011. 73: 25-31.Tamura T, Kurata M, Inoue ES et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyp-ing. Nagoya J. Med. Sci., 2011. 73: 25-31.Furuta T, Shirai N, Kodaira M et al. Pharmaco-genomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther, 2007. 81: 521-8.Furuta T, Shirai N, Kodaira M et al. Pharmaco-genomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther, 2007. 81: 521-8.Furuta T, Shirai N, Sugimoto M et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet., 2005. 20(3): 153-67.Furuta T, Shirai N, Sugimoto M et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet., 2005. 20(3): 153-67.Sugimoto M, Furuta T, Shirai N et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin. Pharmacol. Ther., 2005.; 77(4): 302-11.Sugimoto M, Furuta T, Shirai N et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin. Pharmacol. Ther., 2005.; 77(4): 302-11.Kawamura M, Ohara S, Koike T et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol. Ther., 2003. 17(7): 965-73.Kawamura M, Ohara S, Koike T et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol. Ther., 2003. 17(7): 965-73.Lee YC, Lin JT, Wang HP et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J. Gastroenterol. Hepatol., 2007. 22(8): 1286-92.Lee YC, Lin JT, Wang HP et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J. Gastroenterol. Hepatol., 2007. 22(8): 1286-92.Thomson AB, Sauve MD, Kasam N, Kamitakahara H. Safety of long-term use of protein pump inhibitors. World J. Gastroenterol, 2010. 16(19): 2323-30.Thomson AB, Sauve MD, Kasam N, Kamitakahara H. Safety of long-term use of protein pump inhibitors. World J. Gastroenterol, 2010. 16(19): 2323-30.Hu YM, Mei О, Xu XH et al. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese. World J Gastroenterol, 2006. 12(29): 4750-3.Hu YM, Mei О, Xu XH et al. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese. World J Gastroenterol, 2006. 12(29): 4750-3.Furuta T, Sugimoto M, Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromy-cin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment. Pharmacol. Ther., 2007. 26: 693-703.Furuta T, Sugimoto M, Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromy-cin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment. Pharmacol. Ther., 2007. 26: 693-703.Hagymasi K, Mullner K, Herszenyi L, Tulassay Z. Update on the Pharmacogenomics of Proton Pump Inhibitors. Pharmacogenomics, 2011. 12(6): 873-88.Hagymasi K, Mullner K, Herszenyi L, Tulassay Z. Update on the Pharmacogenomics of Proton Pump Inhibitors. Pharmacogenomics, 2011. 12(6): 873-88.Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol, 2003. 43(12): 1316-23.Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol, 2003. 43(12): 1316-23.

The authors declare that there are no conflicts of interest present.